Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]

Product Code:
Publication Date:
January 2016

Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): the future of inhaled insulin in the light of the licensing agreement termination between Sanofi and MannKind Corp for Afrezza; Sanofi’s once-daily fixed-dose combination (FDC), LixiLan (insulin glargine and lixisenatide), and how it compares with Novo Nordik’s Xultophy (insulin degludec plus liraglutide); Novo Nordisk’s investigational long acting glucagon-like peptide-1(GLP-1) agonist, semaglutide; KOLs provide insight on Eli Lilly’s recently launched long acting GLP-1 agonist, Trulicity (dulaglutide) and the potential of GLP-1/insulin combinations and discuss the likely impact of the launch of Eli Lilly’s biosimilar insulin glargine (Basaglar/Abasaglar).

Key Questions Answered in this Update Bulletin:

  • What do KOLs think about the future of inhaled insulin following the termination of Sanofi’s licensing agreement with MannKind for Afrezza? 
  • What are KOLs opinions of pipeline long-acting injectable GLP-1 agonists, Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Phase III product, semaglutide?
  • What factors will drive the uptake of injectable GLP-1 antagonists as greater choice within this therapy class emerges, and what barriers will this class continue to face?
  • What concerns do KOLs have Sanofi’s LixiLan (insulin glargine and the GLP-1, lixisenatide fixed dose combination)?  
  • Where are the potential opportunities for basal insulin/GLP-1 combinations and what are the critical strategic considerations? 
  • How is Eli Lilly’s Basaglar/Abasaglar likely to impact on the use of current basal insulins such as Sanofi’s Lantus, Novo Nordisk’s Tresiba (insulin degludec) and Sanofi’s Toujeo?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved